|
Q4 FY2025
As of Sep 30, 2025
|
Q4 FY2024
As of Sep 30, 2024
|
Q4 FY2023
As of Sep 30, 2023
|
Q4 FY2022
As of Sep 30, 2022
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|
| Cash and restricted cash | |||||
| Accounts receivable, net | |||||
| Inventories, net | |||||
| Advances to suppliers, net | |||||
| Prepayment for an acquisition of a subsidiary | |||||
| Due from a related party | |||||
| Other receivable | |||||
| Loan to a third party | |||||
| Acquisition reversal receivable | |||||
| Prepaid expenses and other current assets | |||||
| Total current assets | |||||
| Biological assets, net | |||||
| Non-Current Assets: | |||||
| Biological assets, net | |||||
| Long-term investments | |||||
| Land use right, net | |||||
| Long-term deposits | |||||
| Prepayment for property and equipment | |||||
| Property and equipment, net | |||||
| Right-of-use assets | |||||
| Intangible assets, net | |||||
| Total non-current assets | |||||
| Total Assets | |||||
| Short-term loans | |||||
| Long-term loans, current portion | |||||
| Accounts payable | |||||
| Deferred revenue, current | |||||
| Proceeds from private placement | |||||
| Due to a related party | |||||
| Convertible notes | |||||
| Due to related parties | |||||
| Remaining acquisition consideration payable | |||||
| Taxes payable | |||||
| Lease liabilities | |||||
| Prepayment from customers | |||||
| Accrued expenses and other current liabilities | |||||
| Total current liabilities | |||||
| Long-term loans, non-current portion | |||||
| Deferred revenue, non-current | |||||
| Deferred tax liabilities | |||||
| Non-Current Liability: | |||||
| Due to related parties | |||||
| Total non-current liability | |||||
| Total liabilities | |||||
| Ordinary shares, value | |||||
| Class A Ordinary Share | |||||
| Class B Ordinary Share | |||||
| Additional paid-in capital | |||||
| Statutory reserves | |||||
| Accumulated deficits | |||||
| Accumulated other comprehensive loss | |||||
| Total shareholders' equity | |||||
| Total Liabilities and Shareholders' Equity | |||||
Loading...